Of note, atorvastatin marginally reduced tumour number in this model, but did not completely abrogate the tumours (Fig. 3C), in stark contrast to the BRAF model (Fig. 1C), suggesting that the inhibitory effects of atorvastatin could in part depend on the timing of the treatment. Here, BRAF is linked to neoplasm.